NICE rebuffs Roche, BMS in round of cancer rejections

Cost-effectiveness watchdogs in the U.K. dealt another couple of blows to pricey cancer drugs. The National Institute for Health and Care Excellence gave a final thumbs-down to Roche's ($RHHBY) breast cancer med Kadcyla, despite the drugmaker's discount offer. Agency reviewers also recommended against using Bristol-Myers Squibb's ($BMY) Opdivo in squamous non-small cell lung cancer, saying the immunotherapy was too costly for its admittedly notable clinical benefits. More from FiercePharma

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.